OBJECTIVE
To evaluate the safety and pharmacology of the intraperitoneal (IP) administration of the antineoplastic agent taxol.
METHODS
Twenty-five pretreated patients who were entered onto a phase I clinical trial; 24 had advanced ovarian cancer. Patients were treated with taxol administered IP in